Serum Homocysteine as One of the Risk Factors of Cerebral Small Vessel Disease in Chinese Patients
PDF

Keywords

Cerebral small vessel disease
Serum homocysteine
Lacunar infarction
White matter lesion

DOI

10.36922/jmn.v5i1.898

Abstract

Objective: This study aimed to determine the risk factors of cerebral small vessel disease (CSVD) from different variables including serum homocysteine (Hcy) in a group of Chinese patients.
Methods: A total of 139 patients with CSVD admitted to the affiliated hospital of Xuzhou Medical University from July 2017 to July 2018 were enrolled. Fifty healthy individuals were selected as controls. According to the diagnostic criteria, the CSVD patients were divided into three groups, namely, lacunar infarction (LI) group (n=59), white matter lesion (WML) group (n=46), and LI+WML group (n=34). The serum Hcy levels of the three groups were observed and compared. Multivariate logistic regression was performed to determine whether a number of variables including serum Hcy level are the risk factors of CSVD.
Results: Hypertension, systolic blood pressure (SBP), diastolic blood pressure (DBP), low-density lipoprotein cholesterol (LDL-C), triglycerides (TGs), fasting blood glucose (FBG), and Hcy were significantly higher in CSVD group than the control group (P < 0.05). The age, gender, SBP, platelet, TG, and Hcy were significantly different between the LI group, WML group, and LI+WML groups (P < 0.05). The age and Hcy level of patients in LI+WML group were higher than those of the LI group and WML group, and the difference was statistically significant (P < 0.05). The level of SBP was higher in the LI group than the WML group (P < 0.05). The Hcy level of patients in the LI group was higher than that in the WML group, but there was no significant difference (P > 0.05). The platelet and TG were significantly higher in WML group than LI group and LI+WML group (P < 0.05). Controlling the influence of sex and age, multivariate logistic regression analysis revealed that the Hcy levels were correlated with the incidence of the CSVD.
Conclusion: Serum Hcy level is a risk factor for CSVD. Regular detection of serum Hcy level and timely intervention may effectively prevent and control the occurrence and development of CSVD.

References

Pantoni L. Cerebral Small Vessel Disease: From Pathogenesis and Clinical Characteristics to Therapeutic Challenges. Lancet Neurol., 2010, 9(7), 689-701.

Ryu, W.S.; Schellingerhout, D.; Ahn, H.S.; Park, S.H.; Hong, K.S.; Jeong, S.W.; Park, M.S.; Choi, K.H.; Kim, J.T.; Kim, B.J.; Han, M.K.; Lee, J.; Cha, J.K.; Kim, D.H.; Nah, H.W.; Lee, S.J.; Cho, Y.J.; Lee, B.C.; Yu, K.H.; Oh, M.S.; Park, J.M.; Kang, K.; Lee, K.B.; Park, T.H.; Park, S.S.; Smith, E.E.; Lee, J.; Bae, H.J.; Kim, D.E. Hemispheric Asymmetry of White Matter Hyperintensity in Association With Lacunar Infarction. J. Am. Heart Assoc., 2018, 7(22), e010653.

Habes, M.; Sotiras, A.; Erus, G.; Toledo, J.B.; Janowitz, D.; Wolk, D.A.; Shou, H.; Bryan, N.R.; Doshi, J.; Völzke, H.; Schminke, U.; Hoffmann, W.; Resnick, S.M.; Grabe, H.J.; Davatzikos, C. White Matter Lesions: Spatial Heterogeneity, Links to Risk Factors, Cognition, Genetics, and Atrophy. Am. Acad. Neurol., 2018, 91(10), e964-75.

Thrippleton, M.J.; Shi, Y., Blair, G.; Hamilton, I.; Waiter,G.; Schwarzbauer, C.; Pernet, C.; Andrews, P.J.; Marshall, I.; Doubal, F.; Wardlaw, J.M. Cerebrovascular Reactivity Measurement in Cerebral Small Vessel Disease: Rationale and Reproducibility of a Protocol for MRI Acquisition and Image Processing. Int. J. Stroke, 2018, 13(2), 195-206.

Cappellari, M.; Zivelonghi, C.; Turcato, G.; Forlivesi, S.; Micheletti, N.; Tomelleri, G.; Bovi, P.; Bonetti, B. A Nomogram to Predict the Probability of Mortality After First-Ever Acute Manifestations of Cerebral Small Vessel Disease. J. Neurol. Sci., 2018, 385, 92-5.

Benjamin, P.; Trippier, S.; Lawrence, A.J.; Lambert, C.; Zeestraten, E.; Williams, O.A.; Patel, B.; Morris, R.G.; Barrick, T.R.; MacKinnon, A.D.; Markus, H.S. Lacunar Infarcts, but Not Perivascular Spaces, Are Predictors of Cognitive Decline in Cerebral Small-Vessel Disease. Stroke, 2018, 49(3), 586-93.

van Sloten, T.T.; Protogerou, A.D.; Henry, R.M.A.; Schram, M.T.; Launer, L.J.; Stehouwer, C.D. Association Between Arterial Stiffness, Cerebral Small Vessel Disease and Cognitive Impairment: A Systematic Review and Meta-Analysis. Neurosci. Biobehav. Rev., 2015, 53, 121-30.

Zhan, Y.; Zhang, Y.; Li, L. Advances in the Study of the Relationship Between Hyperhomocysteinemia and Cerebrovascular Diseases. Chin. J. Clin., 2017, 17(3), 506-9.

Kester, M,I.; Goos, J.D.C.; Teunissen, C.E.; Benedictus, M.R.; Bouwman, F.H.; Wattjes, M.P.; Barkhof, F.; Scheltens, P.; van der Flier, W.M. Associations Between Cerebral Small-Vessel Disease and Alzheimer Disease Pathology as Measured by Cerebrospinal Fluid Biomarkers. JAMA Neurol., 2014, 71(7), 855-62.

Christen, W.G.; Ajani, U.A.; Glynn, R.J.; Hennekens, C.H. Blood Levels of Homocysteine and Increased Risks of Cardiovascular Disease: Causal or Casual. Arch. Internal Med., 2000, 160(4), 422-34.

Wang, J.; Mu, J.; Chen, X. Lin M. Serum Homocysteine and Cerebral Small Vessel Diseases. Int. J. Cerebrovasc. Dis., 2019, 27(4), 280-6.

Tian, R.; Zhou, Y. Accuracy of Glomerular F’fltrafion Rate Estimation in Hypertensive Patients with Diabetic Nephropathy by Three Common Formulas. China Med., 2019, 14(2), 253-5.

Sonoda, M.; Shoji, T.; Kuwamura, Y.; Okute, Y.; Naganuma, T.; Shima, H.; Motoyama, K.; Morioka, T.; Mori, K.; Fukumoto, S.; Shioi, A.; Shimono, T.; Fujii, H.; Kabata, D.; Shintani, A.; Emoto, M.; Inaba, M. Plasma Homocysteine and Cerebral Small Vessel Disease as Possible Mediators Between Kidney and Cognitive Functions in Patients with Diabetes Mellitus. Sci. Rep., 2017, 7(1), 4382.

Miwa, K.; Tanaka, M.; Okazaki, S.; Yagita, Y.; Sakaguchi, M.; Mochizuki, H.; Kitagawa, K. Increased Total Homocysteine Levels Predict The Risk of Incident Dementia Independent of Cerebral Small Vessel Diseases and Vascular Risk Factors. J. Alzheimers Dis., 2016, 49(2), 503-13.

Roussotte, F.F.; Hua, X.; Narr, K.L.; Small, G.W.; Thompson, P.M. Alzheimer’s Disease Neuroimaging Initiative. The C677T Variant in MTHFR Modulates Associations Between Brain Integrity, Mood, and Cognitive Functioning in Old Age. Biol. Psychiatry Cogn. Neurosci. Neuroimaging, 2017, 2(3), 280-8.

Yan, H.; Yan, Z.; Niu, X.; Wang, J.; Gui, Y.; Zhang, P. Dl-3-n- Butylphthalide Can Improve the Cognitive Function of Patients With Acute Ischemic Stroke: A Prospective Intervention Study. Neurol. Res., 2017, 39(4), 337-43.

Ladiges, W. Metabolism and Aging: From Molecular Physiology to Systems Biology: 2015 Meeting Abstracts. Pathobiol. Aging Agerelated Dis., 2015, 5, 30765.

Shen, X. Detection of Homocysteine and Its Clinical Significance. Contemp. Clin. J., 2016, 29(4), 2445.

Kwon, H.M.; Lynn, M.J.; Turan, T.N.; Derdeyn, C.P.; Fiorella, D.; Lane, B.F.; Montgomery, J.; Janis, L.S.; Rumboldt, Z.; Chimowitz, M.I.; SAMMPRIS Investigators. Frequency, Risk Factors, and Outcome of Coexistent Small Vessel Disease and Intracranial Arterial Stenosis: Results From the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis (SAMMPRIS) Trial. JAMA Neurol., 2016, 73(1), 36-42.

Kloppenborg, R.P.; Nederkoorn, P.J.; van der Graaf, Y.; Geerlings, M.I. Homocysteine and Cerebral Small Vessel Disease in Patients With Symptomatic Atherosclerotic Disease. The SMART-MR Study. Atherosclerosis, 2011, 216(2), 461-6.

Khan, U.; Crossley, C.; Kalra, L.; Rudd, A.; Wolfe, C.D.; Collinson, P.; Markus, H.S. Homocysteine and Its Relationship to Stroke Subtypes in a UK Black Population: The South London Ethnicity and Stroke Study. Stroke, 2008, 39(11), 2943-9.

Jiang, X. Diagnostic Value of High Homocysteine Level in Ischemic Cerebrovascular Disease. J. Hunan Normal Univ. (Med. Ed.), 2018, 15(1), 136-8.

Tang, J.; Fu, J. Pathogenesis of Cerebrovascular Disease. Int. J. Cerebrovasc. Dis., 2013, 21(4), 293-8.

Autenrieth, C.S.; Evenson, K.R.; Yatsuya, H.; Shahar, E.; Baggett, C.; Rosamond, W.D. Association Between Physical Activity and Risk of Stroke Subtypes: The Atherosis Risk in Communities Study. Neuroepidemiology, 2013, 40(2), 109-16.

Schilling, S.; Tzourio, C.; Dufouil, C.; Zhu, Y.; Berr, C.; Alpérovitch, A.; Crivello, F.; Mazoyer, B.; Debette, S. Plasma Lipids and Cerebral Small Vessel Disease. Neurology, 2014, 83(20), 1844-52.

Ji, T.; Zhao, Y.; Liu, Z.; Wang. J.; Cui, Y.; Duan, D.; Chai, Q.; Zhang, H. Effect of Low-Dose Statins and Apolipoprotein E Genotype on Cerebral Small Vessel Disease in Older Hypertensive Patients: A Subgroup Analysis of a Randomized Clinical Trial. J. Am. Med. Dir. Assoc., 2018, 19(11), 996-1002.

Bath, P.M.; Wardlaw, J.M. Pharmacological Treatment and Prevention of Cerebral Small Vessel Disease: A Review of Potential Interventions. Int. J. Stroke, 2015, 10(4), 469-78.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.